New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
08:49 EDTGSK, THRXGSK, Theravance announce Phase III study of FF/VI in Japan
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid, or ICS, fluticasone furoate and long-acting beta2 agonist, or LABA, vilanterol, or FF/VI. The study will evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease, or COPD. Positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan. The study is a 12 week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once daily compared with VI 25mcg once daily, administered via the Ellipta inhaler. Patients included in the study will have a history of COPD with at least one exacerbation in the year prior to screening and will demonstrate current symptoms of COPD. The study seeks to enrol approximately 1580 patients from across 250 study centres worldwide, including approximately 350 patients from centres in Japan.
News For GSK;THRX From The Last 14 Days
Check below for free stories on GSK;THRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
15:35 EDTGSKGlaxoSmithKline receives FDA approval for Arnuity Ellipta in the U.S.
Subscribe for More Information
11:44 EDTGSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
08:30 EDTGSKPernix closes acquisition of Treximet
Subscribe for More Information
08:29 EDTGSKPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:04 EDTGSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
August 15, 2014
06:34 EDTGSKLawyer says GSK connected investigators to not appeal ruling, Reuters says
Defense lawyer Zhai Jian said GlaxoSmithKline connected corporate investigator Peter Humphrey and his American wife are not aiming to appeal a Chinese court's prison sentence ruling, according to Reuters, citing comments from Jian. Reference Link
August 13, 2014
16:19 EDTGSKOn The Fly: Closing Wrap
Subscribe for More Information
13:13 EDTGSKInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
August 12, 2014
07:15 EDTGSKWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:18 EDTGSKGSK CEO faces pressure as company deals with weak sales, allegations, WSJ says
Subscribe for More Information
August 11, 2014
12:57 EDTGSKGlaxoSmithKline facing new bribery allegations in Syria, Reuters reports
Subscribe for More Information
08:47 EDTGSKGlaxo to conduct Ebola vaccine trials later this year, Guardian says
Subscribe for More Information
August 8, 2014
09:03 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
06:18 EDTGSKRoyal Bank of Scotland's Hampton leads race to become new GSK chair, FT reports
Royal Bank of Scotland (RBS) Chairman Philip Hampton is the frontrunner to succeed Christopher Gent as chairman of GlaxoSmithKline (GSK), the Financial Times reports, citing sources. Gent will step down from his role at GSK next year. Hampton is not expected to step down from RBS until after May's general election, the sources say. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use